



Contacts: Robert Jaffe/Evan Pondel  
PondelWilkinson Inc.  
(310) 279-5980

## **LANNETT ANNOUNCES POSITIVE RESULTS OF FACILITIES INSPECTION**

**Philadelphia, PA – October 6, 2008** – Lannett Company, Inc. (AMEX: LCI) today said that the U.S. Food and Drug Administration (FDA) recently completed an inspection of two of the company’s manufacturing facilities, including quality systems. The two-year annual cGMP audit concluded with a total of four minor observations.

“Our customers will be delighted with the favorable outcome of the FDA’s most recent cGMP inspection of our facilities, particularly in light of the high number of major deficiency notices recently received by other generic drug manufacturers,” Arthur Bedrosian, president and chief executive officer of Lannett. “The results of these inspections underscore Lannett’s commitment to quality and regulatory excellence. Lannett employees put forth a tremendous effort to ensure that our manufacturing facilities meet the most rigorous standards.”

Bedrosian added that the four minor observations were corrected by the conclusion of the inspection.

### **About Lannett Company, Inc.:**

Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of indications. For more information, visit the company’s website at [www.lannett.com](http://www.lannett.com).

This news release contains certain statements of a forward-looking nature relating to future events or future business performance. Any such statements, including, but not limited to, the results of FDA inspections of Lannett’s manufacturing facilities, pending ANDAs and products in various stages of development, whether expressed or implied, are subject to risks and uncertainties which can cause actual results to differ materially from those currently anticipated due to a number of factors which include, but are not limited to, the difficulty in predicting the timing or outcome of FDA or other regulatory approvals or actions, the ability to successfully commercialize products upon approval, Lannett’s estimated or anticipated future financial results, future inventory levels, future competition or pricing, future levels of operating expenses, product development efforts or performance, and other risk factors discussed in the company’s Form 10-K and other documents filed with the Securities and Exchange Commission from time to time. These forward-looking statements represent the company’s judgment as of the date of this news release. The company disclaims any intent or obligation to update these forward-looking statements.

###